INNPF Stock Chart & Stats
$1.56
-$0.06(-2.45%)
At close: 4:00 PM EDT
$1.56
-$0.06(-2.45%)
Day’s Range― - ―
52-Week Range$1.25 - $13.22
Previous CloseN/A
Volume200.00
Average Volume (3M)17.00
Market Cap
$6.10M
Enterprise Value$8.16M
Total Cash (Recent Filing)$6.44M
Total Debt (Recent Filing)$1.66M
Price to Earnings (P/E)―
Beta-0.34
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding4,498,772
10 Day Avg. Volume20
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue0.35
Enterprise Value/Gross Profit0.38
Enterprise Value/Ebitda-7.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsGross margins near 90% indicate favorable economics on the company’s products and formulations. If sustained, this provides meaningful capacity to fund research, commercialization, and operating expenses, while giving management more flexibility to improve profitability as revenue scales.
Moderate LeverageModerate leverage and positive shareholders’ equity provide a financial base while the company works toward profitability. Although debt has increased, the current capital structure is less burdensome than a highly leveraged profile and may preserve some flexibility for business development.
Losses Have NarrowedThe substantial reduction in losses from earlier periods suggests that management has improved the company’s earnings profile over time. This progress does not yet establish profitability, but it supports the possibility that continued operating discipline and revenue development could reduce the remaining deficit.
Bears Say
Persistent UnprofitabilityThe company remains loss-making despite its strong gross margin, indicating that operating expenses and investment needs still exceed the contribution from revenue. Continued negative earnings can restrict internally funded growth and leave profitability dependent on successful execution and future scale.
Revenue ContractionDeclining revenue weakens the foundation for operating leverage and makes it harder to convert the company’s high gross margin into sustainable earnings. A continuing contraction would reduce resources available for product development and increase pressure on management to restore demand.
Cash Burn And Funding RiskNegative operating and free cash flow show that the business is currently consuming cash rather than funding itself. The reversal from positive cash generation in 2025 raises execution concerns and could increase reliance on financing if losses and investment requirements persist.
InnoCan Pharma News
INNPF FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was $1.25 and its highest was $13.22 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is $6.10M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Dec 02, 2026 which is in 37 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on Aug 31, 2026. The company reported -$0.007 earnings per share for the quarter.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -$0.007 in its last earnings report. Following the earnings report the stock price went down -12.684%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in INNPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.
Technical Analysis
Ownership Overview
0.88%
Insiders
―
Mutual Funds
― Other Institutional Investors
99.12% Public Companies and
Individual Investors